contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-technologies-plc-managers-transactions-december-29-2025-200-pm-eet

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Well yeah, the horseman from the car dealer family seems to have been the largest participant in the offering with a block of 500,000 shares. Personally, this doesn’t convince me all that much.

The changes in the shareholder list look unprecedented.

Aiforia’s new shareholder list. Kyösti Kakkonen (Joensuun Kauppa Ja Kone Oy) as a new owner directly at 30th place.                   Aiforia              Aiforia - Osakkeenomistajat    Aiforia on lääketieteen ohjelmistoyritys, joka tarjoaa patologeille ja tutkijoille kliinisissä, prekliinisissä ja akateemisissa laboratorioissa tehokkaan syväoppivan tekoälyohjelmiston.

Inderes’ extensive report: “In the United States, the customer can also self-validate an AI model they have developed for clinical use (referred to in the US by the term LDT, Lab Developed Test). In these cases, Aiforia sells its software for research purposes and the customer handles the validation for clinical use themselves. In this way, Aiforia can offer its software to clinical customers without FDA approval even in the United States, such as in the Mayo Clinic customer relationship won at the end of 2021. In our assessment, ready-made FDA- approved products would nonetheless be necessary for broader market formation in the United States.” A major US cancer research institute would obviously be a big reference, whether it’s Dana-Farber or something similar. Especially if they can achieve commercial AI model cooperation, like with Mayo. Aiforia states that spatial biology is precisely at the center. So, not just what cells, but where they are spatially located. Immune cells, for example, can have different functions in different parts of a cancerous tumor and its environment.

Aiforia lacks FDA marketing authorization. “FDA clearance is essential in the United States for medical devices, including AI-powered diagnostic solutions, to be sold and used in clinical settings. Without it, the devices or software may only be available for research or other non-clinical purposes.”

It might be worth noting that, at least in light of Aiforia’s press release, the latest US order is for scientific research use, rather than routine clinical use with large patient datasets. A good reference for sure, but it might not have extraordinary significance for Aiforia’s cash flow.

Still hoping for another announcement since the CEO spoke about potentially two deals before the end of the year; whichever way this one came through, one was rumored to be via Siemens Healthineers. It gave the share price a nice initial boost, but I’m more anxious to see if I’m on the list of the 100 largest shareholders in the upcoming update—the share issue shuffled the deck a bit.

Aiforia Technologies

Aiforia Technologies Plc – Managers’ Transactions – Thomas Rosqvist Aiforia Technologies Plc, MANAGERS’ TRANSACTIONS, December 29, 2025 2:00 p.m. EETAiforia Technologies Plc has received a notificatio...

Aiforia Technologies Plc – Managers’ Transactions – Thomas Rosqvist Aiforia Technologies Plc, MANAGERS’ TRANSACTIONS, December 29, 2025 2:00 p.m. EETAiforia Technologies Plc has received a notification from Thomas Rosqvist, Aiforia Technologies Plc's Chief Technology Officer and a member of management team, of a transaction made with Aiforia Technologies Plc’s financial instrument, according to the Article 19 of EU Market Abuse Regulation.Detailed information about the transaction is given here under.Aiforia Technologies Plc - Managers' transactions - Rosqvist____________________________________________Person subject to the notification requirement Name: Rosqvist, Thomas Position: Other senior manager Issuer: Aiforia Technologies Plc LEI: 743700TJRVBX7420Y723Notification type: INITIAL NOTIFICATION Reference number: 135626/5/6____________________________________________Transaction date: 2025-12-29 Venue not applicable Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Instrument name: Aiforia Technologies 2025D Nature of the transaction: ACCEPTANCE OF A STOCK OPTION (X) Linked to stock option programmeTransaction details (1): Volume: 50,000 Unit price: 0.00 EURAggregated transactions (1): Volume: 50,000 Volume weighted average price: 0.00 EUR&nbsp;Further inquiries Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc tel. +358 405 009 878 <a href="https://investors.aiforia.com/">https://investors.aiforia.com/</a>&nbsp;Certified Adviser&nbsp; UB Corporate Finance Ltd ubcf@unitedbankers.fi&nbsp;About Aiforia&nbsp;Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.&nbsp;Find out more at <a href="http://aiforia.com">www.aiforia.com</a>